anti-dumping tariff on ofloxacin manufactured in China to be applicable in India
The Chinese drug ofloxacin, which is used to treat specific illnesses, should be subject to anti-dumping duties for five years, according to the trade ministry’s recommendation. This will protect domestic producers from low-cost imports from the neighbouring nation.
Following an investigation, the Directorate General of Trade Remedies (DGTR) came to the conclusion that the product had been exported to India at dumped prices, which had an effect on the domestic industry. They therefore recommended placing a duty on imports of “ofloxacin” and its intermediates from China.
The directorate stated in a notification that “the authority believes it necessary and proposes implementation of the anti-dumping charge for a term of 5 years.” Bronchitis, pneumonia, infections of the skin, bladder, urinary system, and prostate are just a few of the illnesses that are treated with ofloxacin.
Following a complaint from Aarti Drugs Ltd on the dumping and beginning of the investigation, DGTR carried out the investigation. The ministry is managed by the directorate.
The recommended duty is in the range of US $0.53 to US $7.03 per kilogramme. The decision to enforce these obligations rests with the finance ministry. The World Trade Organization (WTO) regime permits the implementation of anti-dumping duties.